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Objective: Cystatin C (Cys C) is a marker of renal dysfunction. Prior studies have shown that blood Cys C is related
to the prognosis of coronary heart disease. The aim of the present study was to evaluate the long-term prognostic
impact of Cys C on acute coronary syndrome (ACS) octogenarians with diabetes mellitus (DM).
Methods: We enrolled 660 consecutive ACS octogenarians who underwent coronary angiography and were
classified into two groups based on diabetes. The baseline characters and Cys C level were measured on admission.
Survival curve was calculated using the Kaplan-Meier method. Multivariate Cox regression was used to identify
predictors of mortality and of major adverse cardiac events (MACE) rate.
Results: There were 223 and 398 patients in groups DM and non-DM who fulfilled the follow-up. The average
follow-up period was 28 (IQR 16–38) months. Diastolic blood pressure (DBP) was lower, ratios of hypertension and
chronic renal failure (CRF), fasting blood glucose, HbA1c and Cys C levels were higher in DM group than those in
non-DM group (P<0.01). The cumulative survival of DM group was significantly lower than that of non-DM group
in the long term (P = 0.018). All cause mortality and MACE of DM group were higher than those of non-DM
group (P<0.05). The plasma Cys C concentration (OR = 3.32, 95% CI = 1.18-10.92, P = 0.023) was the uniqueness
independent predictor for long-term all cause mortality. The plasma Cys C concentration (OR = 2.47, 95% CI =
1.07-7.86, P = 0.029) and Genesis score (OR = 1.01, 95% CI = 1.00-1.03, P = 0.043) were independent predictors for
MACE in DM group. ROC curve analysis showed that the predictive cut-off value of Cys C for mortality of DM group
was 1.605 (0.718, 0.704).
Conclusions: Cys C is an independent predictor for long-term mortality and MACE of ACS octogenarians with DM.
Keywords: Acute coronary syndrome, Cystatin C, Octogenarian, Diabetes mellitus, PrognosisIntroduction
The older population represents a growing proportion of
the general population. Octogenarian (age >80 years old)
will increase from the current ratio of 1 in 35 to more
than 1 in 12 by the year 2050 [1]. The increasing preva-
lence of coronary artery disease (CAD) is associated with
aging. Compared with younger patients, elderly patients
who undergo coronary angiography (CAG) present more
complex lesions, higher comorbidity, poorer clinical out-
comes and higher mortality [2,3].* Correspondence: chenyundai301@gmail.com
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stated.Cystatin C (Cys C) is a cysteine protease inhibitor with
a low-molecular weight (13 kD) that is produced by all
nucleated cells at a constant rate. It is freely filtered
across the glomerular membrane and is not influenced
by age, sex, muscle mass, exercise or diet [4]. Therefore,
the serum Cys C level is a superior marker for the evalu-
ation of renal function compared to other markers such
as serum creatinine or creatinine clearance [5]. Over the
last few years it has been suggested that high Cys C con-
centration is related directly to both inflammation and
atherosclerosis [6]. Cys C level is also associated with
the prognosis of CAD in the general population [7-11].
Diabetes mellitus (DM) is an established risk factor and
equivalent of CAD. Patients with CAD and DM are atThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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poor. Prior studies show a positive relationship of serum
Cys C level with the incidence of type 2 DM [12]. The
findings strongly suggest Cys C is associated with not
only the development of cardiovascular disease (CVD)
but also the incidence of type 2 DM. Therefore, we
presume that Cys C plays an important role during
the short and long term prognosis of an ACS patient
with DM.
To date, the prognostic value of Cys C in very old
(age >80) ACS patients, especially with DM, remains
unclear. The prior studies were simply focused on the
ACS patients at the age of about 60 years old. There-
fore, the aim of the present study is to evaluate long-
term prognostic impact of plasma Cys C on Chinese
ACS octogenarians with DM.
Methods
Study population
From January 2006 to December 2011, a total of 660
consecutive patients with ACS (age > 80 years old), who
were referred to our hospital for percutaneous coronary
intervention (PCI), were enrolled in this study. The in-
clusion criteria were: (1) patients with a complete cli-
nical history; (2) a diagnosis of ACS that was classified
as unstable angina pectoris (UAP), non-ST-segment ele-
vated myocardial infarction (NSTEMI) or ST-segment
elevated myocardial infarction (STEMI) [13] and (3)
recent coronary angiography (CAG). Those with acute
infection, chronic hepatic dysfunction, nutritional de-
rangements, malignancy, severe valvular heart disease,
severe heart failure, dysthyroidism or other severe me-
dical illnesses were excluded.
All patients consented in written to their participation
in the study, and the study agreement was approved by
the Chinese People’s Liberation Army General Hospital
research ethics committee and complied with the Dec-
laration of Helsinki.
Data collection
The clinical characteristics of all patients were recorded
on admission. These included age, gender, heart rate
(HR), body mass index (BMI), systolic and diastolic
blood pressure (SBP, DBP), eject fraction (EF), diabetes,
primary hypertension, hyperlipidemia, previous myocar-
dial infarction (MI), previous stroke, chronic renal failure
(CRF), smoking history, and cardiovascular medication.
Fasting blood samples were drawn prior to angiography to
evaluate blood biochemistry. The fasting blood glucose
(FBG), HbA1c, triglyceride (TG), total cholesterol (TC),
low density lipoprotein-C (LDL-C), serum creatinine
(CRE), urea nitrogen (BUN), and Cys C were analyzed. For
all patients, renal function was assessed using the baseline
estimated glomerular filtration rate (eGFR). Impaired renalfunction was defined as an eGFR <60 mL/min/1.73 m2.
The creatinine was standardized using a calibration
equation called Jaffe’s kinetic method [14]:
Scr mg=dlð Þ ¼ 0:795 enzymatic method Scr mg=dLð Þ½  þ 0:29
The estimated glomerular filtration rate (eGFR) was
calculated using the Chinese modified Modification of
Diet in Renal Disease (C-MDRD) equation [15]:
eGFR ml=min=1:73m2
  ¼ 175  standardized creatine mg=dlð Þ
− 1:234  age yearð Þ− 0:179
 0:79 if femaleð Þ
Coronary angiography
CAG was performed on all patients after admission.
CAD was defined as an obstructive lesion causing ≥ 50%
reduction of lumen diameter in at least one of the co-
ronary arteries. The severity of CAD was evaluated using
the Gensini score [16].
The 8 variables used in the GRACE risk model in-
cluded older age, Killip class, systolic blood pressure,
ST-segment deviation, cardiac arrest during presenta-
tion, serum creatinine level, positive initial cardiac bio-
markers, and heart rate. The sum of scores was applied
to determine the corresponding all cause mortality in-
hospital and from hospital discharge to 6 months [17].
Gensini and GRACE scores for each enrolled patient
were recorded by observers who were blinded to the re-
sults of laboratory tests and grouping.
Population grouping and follow-up
Our patients were divided into DM group and non-DM
group. The definition of DM was such that a person had
an FBG higher than 7 mmol/L, or a 2 hour PBG or ran-
dom glucose higher than 11.1 mmol/L. All patients were
regularly followed at 6-month intervals for the first 12
months, and thereafter every 12 months. All patients
were advised to contact the outpatient clinic as soon as
possible after a symptomatic event. Long-term outcomes
during the follow-up were compared between the two
groups.
A major adverse cardiac event (MACE) included any
of the following: death for any cause, MI, and need for
repeat revascularization (repeat PCI or coronary artery
bypass grafting (CABG)).
Statistical analysis
Continuous variables were expressed as the mean ±
standard deviation (SD) or median (with inter quartile
range (IQR)). The t test was used if continuous variables
were normally distributed, while the Wilcoxon two-
sample test was used if continuous variables were not
normally distributed. Categorical data were summarized
Table 1 Study population clinical characteristics in ACS octogenarians with DM and non-DM
Characteristic, n (%) DM group (n=223) Non-DM group (n=398) P Value
General conditions
Age (years) 81.74 ± 2.54 81.99 ± 2.21 0.201
Male, n (%) 152 (68.16) 299 (75.13) 0.078
HR (bpm) 75.91 ± 13.74 74.23 ± 14.34 0.156
BMI (kg/m2) 24.82 ± 3.30 24.45 ± 3.45 0.193
TG 1.63 ± 0.79 1.54 ± 0.68 0.136
TC 3.86 ± 1.13 3.95 ± 1.11 0.336
LDL-C 2.28 ± 0.64 2.32 ± 0.57 0.423
FBG (mmol/L) 8.52 ± 2.26 6.36 ± 2.56 0.000
HbA1c (%) 8.62 ± 2.17 6.64 ± 1.21 0.000
SBP (mmHg) 138.85 ± 20.74 136.07 ± 22.01 0.124
DBP (mmHg) 69.68 ± 12.04 72.62 ± 12.09 0.004
EF (%) 55.72 ± 8.81 55.35 ± 10.11 0.647
Genesis score 47(IQR 21.5–73) 44 (IQR 18–76) 0.202
GRACE score 138 (IQR 131–153) 138 (IQR 131–151) 0.707
Risk factors
Hypertension 193 (86.55) 286 (71.86) 0.000
Hyperlipoidemia 55 (24.66) 88 (22.11) 0.532
Previous MI 35 (15.70) 81 (20.35) 0.187
Previous stroke 48 (21.52) 78 (19.60) 0.639
CRF 36 (16.14) 39 (9.80) 0.008
Smoking 63 (28.25) 87 (21.86) 0.092
Renal function indicators
CRE (μmol/L) 85.45 (IQR 72.95–112.10) 85.25 (IQR 72.58–99.93) 0.620
BUN (mmol/L) 6.85 (IQR 5.51–9.42) 6.66 (IQR 5.11–8.18) 0.078
Cystatin C(mg/L) 1.55 (IQR 1.24–1.90) 1.38 (IQR 1.23–1.78) 0.009
e-GFR (ml/min/1.73 m2) 68.67 (IQR 55.97–82.14) 72.55 (IQR 63.08–81.74) 0.106
Cardiovascular medications
Aspirin 219 (98.21) 384 (96.48) 0.328
Clopidogrel 212 (95.07) 380 (95.48) 0.973
Beta-blocker 149 (66.82) 244 (61.31) 0.201
ACEI/ARB 143 (64.13) 224 (56.28) 0.068
Statin 204 (91.48) 370 (92.96) 0.608
ACS type 0.178
STEMI 22 (9.87) 54 (13.57)
NSTEMI 27 (12.11) 34 (8.54)
UAP 174 (78.02) 310 (77.89)
Treatment strategy
PCI (emergency PCI) 146 (13) 268 (39) 0.636
CABG 9 17 0.888
Intensive medcine 58 113 0.524
DM =Diabetes mellitus, HR= Heart rate, BMI= body mass index, TG =triglyceride, TC= total cholesterol, LDL-C= low density lipoprotein-C, FBG=fasting blood
glucose, SBP=systolic blood pressure, DBP=diastolic blood pressure, EF=eject fraction, MI=myocardial infarction, CRF=chronic renal failure, CRE=serum creatinine,
BUN=urea nitrogen, eGFR=estimated glomerular filtration rate, ACEI=angiotensin converting enzyme inhibitor, ARB=angiotensin receptor blocker, ACS= acute
coronary syndrome, STEMI= ST-segment elevated myocardial infarction, NSTEMI= non-ST-segment elevated myocardial infarction, UAP= unstable angina pectoris.
PCI=percutaneous coronary angiography, CABG=coronary artery bypass grafting.
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Figure 1 Kaplan-Meier survival rate curves for all-cause death
according to diabetes.
Figure 2 Quartile analysis comparing the concentration of
Cys C to the mortality of DM and non-DM group.
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categorical variables. Survival rates were calculated ac-
cording to the Kaplan-Meier method. Survival time was
defined as from the date of coronary angiography to the
date of death as verified during the follow-up. Dif-
ferences between pairs of survival curves were tested by
the log-rank test. A Cox proportional hazards model
was used to identify predictors of mortality. Odds ratios
(ORs) were reported with corresponding 95% confidence
intervals (CIs). Receiver operating characteristic (ROC)
curves were constructed for discrimination between
survived and dead patients. The areas under the curve
(AUC) were compared by using Hanley and McNeil
method. All P values were two-sided, and a P value < 0.05
was considered statistically significant. Statistical analysis
was performed using the Statistical Package for Social
Sciences, version 17.0 (SPSS, Chicago, Illinois).
Results
Baseline characteristics of patients
Baseline clinical characteristics and clinical event data
were fully documented for 621 (621/660, 94.09%) en-
rolled patients during the follow-up period. 14 patients
in DM group and 25 patients in non-DM group were
lost during the follow-up because of the wrong tele-
phone number. Of the 621 patients, 223 (35.91%) pa-
tients had diabetes and 398 (64.09%) patients did not
have diabetes (1: 1.78). The ratio of ACS octogenarians
with DM was over one third.
The baseline clinical characteristics of the two groups
were shown in Table 1. As compared with those in the
non-DM group, patients in DM group had lower DBP
(P<0.01) and higher level of FBG (P<0.01) and HbA1c
(P<0.01), while other characteristics including age, gen-
der, HR, BMI, TG, TC, LDL-C, SBP, EF, Genesis score
and GRACE risk score were not different (P>0.05). The
morbidities of hypertension and CRF were higher in DM
group than in non-DM group (P<0.01). Among renal
function indicators, only plasma Cys C concentration in
DM group was higher than that in non-DM group (1.55
(IQR 1.24-1.90) vs. 1.38 (IQR 1.23-1.78) mg/L, P = 0.009).
In addition, no differences were found in medication use
and treatment strategies between the two groups. No dif-
ferences were found in ACS type (P>0.05).
Long- term clinical outcomes
The duration of the follow-up was between 13 and 79
months (median 28 months, IQR 16–38 months). Dur-
ing the follow-up period, 40 patients (17.94%) died and
15 patients (6.73%) experienced reinfarction or revascu-
larization, and the rate of MACE was 24.67% in DM
group. 44 patients (11.06%) died and 25 patients (6.28%)
experienced reinfarction or revascularization, and the
rate of MACE was 17.34% in non-DM group. The allcause mortality and MACE rate in DM group were higher
than those in non-DM group (P = 0.011, P = 0.037). The
rates of reinfarction and revascularization were not signifi-
cantly different between the two groups (P>0.05). Figure 1
shows the Kaplan-Meier survival curve for all-cause death
according to diabetes. There was a significant difference
between the two groups (P = 0.018). DM group had a high
risk of all-cause death.
Concentration of Cys C relative to all-cause death
according to quartile analysis was compared between
DM group and non-DM group. Quartiles (Q) ranges of
Cys C were: Q1: 1.11(0.52-1.22), Q2: 1.31(1.23-1.43), Q3:
1.59(1.44-1.82), and Q4: 2.23(1.83-5.12) mg/L. As de-
tailed in Figure 2, the mortality of each quarter in DM
group was higher than that in non-DM group. The dif-
ferences increased along with concentration of Cys C,
and in ranges Q3 (P = 0.016) and Q4 (P = 0.036) the dif-
ferences were significant. The mortality increased with
the concentration of Cys C and the tendency was
Figure 3 ROC curves for Cys C and other renal function
indicators for discrimination between survived and dead
patients in DM group.
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group, the mortality was higher than others only in
range Q4 (P = 0.01), and the differences in ranges Q1 to
Q3 were not significant.
Risk factors associated with mortality during follow-up
We performed a Cox regression analysis to determine the
factors that were associated with all cause death in DM
group and non-DM group at the end of the follow-up.
After being adjusted for age, gender, heart rate, BMI, TG,
TC, LDL-C, FBG, HBA1c, SBP, DBP and EF, the plasma
Cys C concentration (OR = 3.32, 95% CI = 1.18-10.92,
P = 0.023) was the unique independent predictor for long-
term mortality, and the plasma Cys C concentration
(OR = 2.47, 95% CI = 1.07-7.86, P = 0.029) and Genesis
score (OR = 1.01, 95% CI = 1.00-1.03, P = 0.043) were in-
dependent predictors for MACE in DM group.
Diagnostic power of Cys C and other renal function
indicators for mortality during follow-up
The respective predictive cut-off values were constructed
according to the ROC curves for Cys C and other renalTable 2 Performances of measures of renal function for predi
Indicators Cut-off point Sensitivity 1-s
Cys C 1.605 0.718 0.7
CRE 96.9 0.667 0.6
BUN 7.75 0.692 0.6
eGFR 90.2 0.692 0.6
CI= confidence interval, AUC= areas under the curve. Cys C= Cystatin C, CRE= serum
filtration rate.function indicators for discrimination between survived
and dead patients in DM group (Figure 3). Using these
cut-off points, Cys C showed higher sensitivity and spe-
cificity with a greater area under the ROC curve than
other biomarkers (Table 2). The predictive cut-off value
of Cys C for mortality of DM group was 1.605 mg/L.
Discussion
In the present study, we have found that plasma Cys C
concentration was an independent predictor for long-
term mortality and MACE in ACS octogenarians with
DM after controlling for conventional cardiovascular
risk factors, but not for those without DM. To the best
of our knowledge, our study is the first prospective co-
hort study to enroll a large number of Chinese ACS oc-
togenarians with DM, the duration of the follow-up is
the longest (from 13 month to 79 month) and the
follow-up rate is the highest.
Previous studies show that mild renal insufficiency is
a major risk factor for CVD and predicts the worst
outcomes [18]. In recent years, general studies have indi-
cated that Cys C was proposed as a more reliable marker
of renal function than serum creatinine [19], particularly
in the detection of small reductions in GFR [20]. Factors
that influence serum creatinine levels do not affect Cys
C levels. In the present study, we found that among the
respective predictive cut-off values, Cys C showed higher
sensitivity and specificity with a greater area under the
ROC curve than other renal function biomarkers. How-
ever, some other studies reported that serum Cys C had
limited predictive capacity for the early detection of
acute kidney injury after cardiopulmonary bypass sur-
gery in infants and young children. The main reasons
lied in the difference in enrolled population. The age in
those other studies was younger than 3 year old [21].
Study has demonstrated that high Cys C concentration
is related directly to both inflammation and atheroscle-
rosis [22]. Cys C has also been shown to be independent
prognostic information in cardiovascular disease in the
general population [23-27]. In addition, study has also
suggested that patients with higher Cys C concentration
appear to have high risk of CAD, and the level of Cys C
was also related to long term all cause and cardiovascular
mortality in patients referred to coronary angiographyction of mortality
pecificity 95% CI AUC P value
04 0.703; 0.861 0.782 P<0.01
87 0.645; 0.829 0.737 P<0.01
6 0.612; 0.813 0.712 P<0.01
33 0.172; 0.360 0.266 P<0.01
creatinine, BUN= blood urea nitrogen, e-GFR= estimated glomerular
Fu et al. Cardiovascular Diabetology 2013, 12:157 Page 6 of 7
http://www.cardiab.com/content/12/1/157[24,28,29]. Consistent studies have reported Cys C con-
centration was associated with all cause death risk for
non-STEMI ACS [30], and prognostic value for patients
with STEMI undergoing primary PCI [31]. On the con-
trary, a study has shown Cys C concentration was not re-
lated to the new onset DM [32]. The main reasons lied in
the difference in enrolled population and the combined
disease. The main diseases in the study were hypertension
with pre-diabetes, and the average years were 69.4 year
old. In the present study, we found that the prognosis
value of Cys C in ACS octogenarians with DM was inde-
pendent of renal function impaired, and plasma Cys C
concentration played the most obvious role and was an ef-
fective indicator for all cause mortality. Cys C as a cysteine
proteinase inhibitor may play an important role in the
pathogenesis of atherosclerosis. Cys C is associated with
cardiovascular risk factors as well as inflammation, which
may promote atherosclerosis. Some studies have suggested
that inflammatory cytokines related to atherosclerosis
stimulate lysosomal cathepsins, which may be associated
with increased Cys C levels to counterbalance the elastoly-
tic activity of cathepsins [22]. All these effects may cause
the worse vascular endothelial damage, inflammation and
atherosclerosis in DM patients.
In addition, previous studies show age was a very im-
portant risk factor for predicting prognosis of ACS pa-
tients in general population. In GRACE study, age was
the most important factor affecting in-hospital and six-
month discharge mortality, However, for very old pa-
tients (age >80 years old), the ratio of age score was too
high in the GRACE risk score, and all patients enrolled
in our study were at very high risk according to GRACE
risk score. The need of searching for new biomarkers
with better and more accurate profiles to evaluate prog-
nosis of these very high risk ACS patients at the age
of > 80 years old has been very intense. Our results
indicated, Cys C concentration was an intense bio-
marker for evaluation of prognosis of Chinese ACS
octogenarians with DM and was not influenced by
age. This is the first time to define the cutoff value of
Cys C concentration for predicting all cause mortality
in ACS octogenarians with DM.
As we know, the proportion of ACS with DM in eld-
erly patients is significantly higher than that in the ge-
neral population, the patients are usually very high-risk
groups and have many complications, and the prognosis
of them is poor. Therefore the risk stratification in these
patients is particularly important. Finding accurate indi-
cators which can be used to determine the prognosis of
these patients emerges as a target of interest. In our
study, we analyzed the general conditions and comorbi-
dities in DM and non-DM patients, and the ratio of DM
in the observed Chinese ACS octogenarians was over
one third, which was higher than the prior reports byabout 20-30% [33,34]. The Cys C level was significantly
different, while severity of coronary artery (Genesis
score), GRACE risk score as well as general renal func-
tion indicators were not significantly different between
DM and non-DM patients. All the enrolled patients had
complex, multi-vessel and diffuse coronary artery le-
sions, and were at very high risk. The results of our
study were not completely consistent with the usual
concepts that the renal function was obviously poor and
coronary artery lesions were complicated in DM patients
than those in non-DM patients. It was thus clear that
the impact of DM on the renal function and coronary
artery lesions severity was small in very old age patients.
Some limitations must be considered. Our study was
similar to other single center registries in that it offered
observational data on nonrandomized patients. In ad-
dition, plasma Cys C levels was measured at a single
point in the present study.
Conclusions
All cause mortality and MACE of ACS octogenarians
with DM were higher than those of ACS octogenarians
without DM. Plasma Cys C level was an independent
predictor for long-term mortality and MACE of ACS oc-
togenarians with DM, while not for non-DM patients.
Plasma Cys C level was an accurate biomarker for pre-
dicting the long term prognosis for ACS octogenarians
with DM.
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